- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02926430
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health
18 de febrero de 2019 actualizado por: Janssen Vaccines & Prevention B.V.
A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health
The purpose of this study is to assess the safety and tolerability of 2 single doses of either 5*10^10 viral particles (vp) or 1*10^11 vp of Ad26.RSV.preF,
administered intramuscularly to elderly adults given approximately 12 months apart.
Descripción general del estudio
Estado
Terminado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Intervencionista
Inscripción (Actual)
73
Fase
- Fase 1
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Florida
-
Miami, Florida, Estados Unidos
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
60 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
Sí
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- Each participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study, is willing to participate in the study and attend all scheduled visits, and is willing and able to comply with all study procedures and adhere to the prohibitions and restrictions specified in this protocol
- Before randomization, a woman must be: postmenopausal - A postmenopausal state is defined as no menses for 12 months without an alternative medical cause; and not intending to conceive by any methods
- From the time of first vaccination until 3 months after the first dose of study vaccine, and from the second vaccination through 3 months after, a man who has not had a vasectomy (or if a vasectomy was performed less than 1 year ago and the absence of sperm cannot be verified)
- In the investigator's clinical judgment, participant must be either in good or stable health. Participants may have underlying illnesses such as hypertension, type 2 diabetes, hyperlipoproteinemia, or hypothyroidism, as long as their symptoms/signs are medically controlled. If they are on medication for a condition, the medication dose must have been stable for at least 12 weeks preceding vaccination and expected to remain stable for the duration of the study. Participants will be included on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening
- Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the central laboratory normal reference ranges and additionally within the limits of toxicity Grades 1 or 2 according to the US Food and Drug Administration (FDA) toxicity tables (for tests in the FDA table ), the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
Exclusion Criteria:
- Participant has acute illness (this does not include minor illnesses such as diarrhea) or temperature greater than or equal to (>=) 38.0 degree celsius within 24 hours prior to the first dose of study vaccine; enrollment at a later date is permitted
- Participant has a serious chronic disorder, including severe chronic obstructive pulmonary disease or clinically significant congestive heart failure, requirement for supplemental oxygen, end stage renal disease with or without dialysis, clinically unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example, compromise well-being) or that could prevent, limit, or confound the protocol-specified assessments
- Participant has had major surgery within the 4 weeks prior to randomization or has planned major surgery through the course of the study
- Participant has chronic active hepatitis B or hepatitis C infection, documented by hepatitis B surface antigen and hepatitis C antibody, respectively
- Participant has human immunodeficiency virus (HIV) type 1 or type 2 infection
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Ad26.RSV.preF 5*10^10 vp (Day 1 and Day 365): Group 1
Participants will receive 5*10^10 viral particles (vp) Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
|
Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
Otros nombres:
|
Experimental: Ad26.RSV.preF 5*10^10 vp (Day 1)- Placebo (Day 365): Group 2
Participants will receive 5*10^10 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
|
Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
Otros nombres:
Participants will receive placebo as formulation buffer.
|
Experimental: Ad26.RSV.preF 1*10^11 vp (Day 1 and Day 365): Group 3
Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and Day 365 (10 to 13 months after first vaccination).
|
Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
Otros nombres:
|
Experimental: Ad26.RSV.preF 1*10^11 vp (Day 1)- Placebo (Day 365): Group 4
Participants will receive 1*10^11 vp Ad26.RSV.preF at Day 1 and placebo on Day 365 (10 to 13 months after first vaccination).
|
Participants will receive placebo as formulation buffer.
Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
Otros nombres:
|
Experimental: Placebo (Day 1 and Day 365): Group 5
Participants will receive placebo at Day 1 and Day 365 (10 to 13 months after first vaccination).
|
Participants will receive placebo as formulation buffer.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination (Day 1)
Periodo de tiempo: 7 days after each vaccination (Day 1)
|
7 days after each vaccination (Day 1)
|
Number of Participants With Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination (Day 365)
Periodo de tiempo: 7 days after each vaccination (Day 365)
|
7 days after each vaccination (Day 365)
|
Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination (Day 1)
Periodo de tiempo: 7 days after each vaccination (Day 1)
|
7 days after each vaccination (Day 1)
|
Number of Participants With Solicited Systemic Adverse Events (AEs) for 7 Days After Each Vaccination (Day 365)
Periodo de tiempo: 7 days after each vaccination (Day 365)
|
7 days after each vaccination (Day 365)
|
Number of Participants With Unsolicited AEs for 28 Days After Each Vaccination
Periodo de tiempo: 28 days after each vaccination (from signing the informed consent form [ICF] to Day 29 inclusive)
|
28 days after each vaccination (from signing the informed consent form [ICF] to Day 29 inclusive)
|
Number of Participants With Serious Adverse Events (SAEs) Throughout Study
Periodo de tiempo: Up to 730 days
|
Up to 730 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Respiratory Syncytial Virus (RSV) Neutralization A2
Periodo de tiempo: Days 1, 29, 183, 365, 393, 547, 730
|
Analysis of RSV A2 neutralizing titers of the vaccine-induced immune response will be assessed.
|
Days 1, 29, 183, 365, 393, 547, 730
|
RSV Fusion Protein (F-protein) Enzyme-linked Immunosorbent Assay
Periodo de tiempo: Days 1, 29, 183, 365, 393, 547, 730
|
Analysis of antibodies binding to RSV F protein in post-fusion and pre-fusion form.
|
Days 1, 29, 183, 365, 393, 547, 730
|
Intracellular Cytokine Staining
Periodo de tiempo: Day 1, 29, 183, 365, 393, 547, 730
|
The activation of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cell subsets and their cytokine expression patterns will be determined by flow cytometry after RSV protein peptide stimulation (including, but not limited to CD4/CD8, interleukin [IL-2], interferon gamma [IFN gamma], tumor necrosis factor alpha [TNF-alpha] and/or activation markers, memory, T-helper [cells] Th1/Th2 subtyping).
|
Day 1, 29, 183, 365, 393, 547, 730
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Actual)
8 de noviembre de 2016
Finalización primaria (Actual)
14 de marzo de 2018
Finalización del estudio (Actual)
29 de enero de 2019
Fechas de registro del estudio
Enviado por primera vez
22 de septiembre de 2016
Primero enviado que cumplió con los criterios de control de calidad
5 de octubre de 2016
Publicado por primera vez (Estimar)
6 de octubre de 2016
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
19 de febrero de 2019
Última actualización enviada que cumplió con los criterios de control de calidad
18 de febrero de 2019
Última verificación
1 de febrero de 2019
Más información
Términos relacionados con este estudio
Otros números de identificación del estudio
- CR108214
- VAC18193RSV1003 (Otro identificador: Janssen Vaccines & Prevention B.V.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Ad26.RSV.preF 5*10^10 vp
-
Janssen Vaccines & Prevention B.V.Terminado
-
Janssen Vaccines & Prevention B.V.TerminadoInfecciones del Tracto Respiratorio | Virus sincitial respiratorioReino Unido, Finlandia, Estados Unidos
-
Janssen Vaccines & Prevention B.V.Terminado
-
Janssen Vaccines & Prevention B.V.Terminado
-
Crucell Holland BVThe PATH Malaria Vaccine Initiative (MVI); Seattle Children's Research Institute...Terminado
-
AerasEuropean and Developing Countries Clinical Trials Partnership (EDCTP)Terminado
-
University of OxfordNational Institute of Allergy and Infectious Diseases (NIAID); Wellcome TrustTerminadoÉbola | Ébola ZaireReino Unido
-
ClinAmygateAswan University HospitalReclutamientoColecistolitiasis | Colecistitis; Cálculo biliar | Colecistitis CrónicaEgipto
-
AerasCrucell Holland BVTerminado
-
London School of Hygiene and Tropical MedicineUniversity of Sierra Leone; Innovative Medicines InitiativeTerminadoEnfermedad del virus del ÉbolaSierra Leona